1
|
Sert B, Gulden G, Teymur T, Ay Y, Turan RD, Unaldi OM, Guzenge E, Erdil HE, Isik S, Oz P, Bozkurt I, Ozer S, Yurdakul T, Kamali O, Ovali E, Tarhan N, Tastan C. Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model. Cancer Gene Ther 2024; 31:387-396. [PMID: 38092962 DOI: 10.1038/s41417-023-00709-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 11/20/2023] [Accepted: 11/27/2023] [Indexed: 03/16/2024]
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy holds great promise as an innovative immunotherapeutic approach for cancer treatment. To optimize the production and application of CAR-T cells, we evaluated the in vivo stability and efficacy capacities of CAR-T cells developed under different conditions. In this study, CAR-T cells were activated using Phytohemagglutinin (PHA) or anti-CD3&anti-CD28 and were compared in an in vivo CD19+B-cell cancer model in mouse groups. Our results demonstrated that CAR-T cells activated with PHA exhibited higher stability and anti-cancer efficacy compared to those activated with anti-CD3&anti-CD28. Specifically, CAR19BB-T cells activated with PHA exhibited continuous proliferation and long-term persistence without compromising their anti-cancer efficacy. Kaplan-Meier survival analysis revealed prolonged overall survival in the CAR-T cell-treated groups compared to the only tumor group. Furthermore, specific LTR-targeted RT-PCR analysis confirmed the presence of CAR-T cells in the treated groups, with significantly higher levels observed in the CAR19BB-T (PHA) group compared to other groups. Histopathological analysis of spleen, kidney, and liver tissue sections indicated reduced inflammation and improved tissue integrity in the CAR-T cell-treated groups. Our findings highlight the potential benefits of using PHA as a co-stimulatory method for CAR-T cell production, offering a promising strategy to enhance their stability and persistence. These results provide valuable insights for the development of more effective and enduring immunotherapeutic approaches for cancer treatment. CAR-T cells activated with PHA may offer a compelling therapeutic option for advancing cancer immunotherapy in clinical applications.
Collapse
Affiliation(s)
- Berranur Sert
- Molecular Biology, Institute of Science and Technology, Üsküdar University, Istanbul, Turkey
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
| | - Gamze Gulden
- Molecular Biology, Institute of Science and Technology, Üsküdar University, Istanbul, Turkey
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
| | - Tarik Teymur
- Molecular Biology, Institute of Science and Technology, Üsküdar University, Istanbul, Turkey
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
| | - Yasin Ay
- Molecular Biology, Institute of Science and Technology, Üsküdar University, Istanbul, Turkey
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
| | - Raife Dilek Turan
- Department of Genetics and Bioengineering, Faculty of Engineering, Cell and Gene Therapy Excellence Center, Yeditepe University, Istanbul, Turkey
| | - Onur Mert Unaldi
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
- Molecular Biology and Genetics Department, Faculty of Engineering and Natural Science, Üsküdar University, Istanbul, Turkey
| | - Elanur Guzenge
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
- Molecular Biology and Genetics Department, Faculty of Engineering and Natural Science, Üsküdar University, Istanbul, Turkey
| | - Hamza Emir Erdil
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey
- Molecular Biology and Genetics Department, Faculty of Engineering and Natural Science, Üsküdar University, Istanbul, Turkey
| | - Sevim Isik
- Molecular Biology and Genetics Department, Faculty of Engineering and Natural Science, Üsküdar University, Istanbul, Turkey
- Stem Cell Studies Application and Research Center (USKOKMER), Üsküdar University, Istanbul, Turkey
| | - Pinar Oz
- Molecular Biology and Genetics Department, Faculty of Engineering and Natural Science, Üsküdar University, Istanbul, Turkey
- Neuropsychopharmacology Application and Research Center (NPFUAM) Neurochemıstry Laboratory Üsküdar University, Istanbul, Turkey
| | | | - Samed Ozer
- Acıbadem Mehmet Ali Aydınlar University, Animal Application and Research Center, İstanbul, Turkey
| | - Tahire Yurdakul
- Molecular Biology, Institute of Science and Technology, Üsküdar University, Istanbul, Turkey
- Stem Cell Studies Application and Research Center (USKOKMER), Üsküdar University, Istanbul, Turkey
| | - Osman Kamali
- Neuropsychopharmacology Application and Research Center (NPFUAM) Neurochemıstry Laboratory Üsküdar University, Istanbul, Turkey
| | - Ercument Ovali
- Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Turkey
| | - Nevzat Tarhan
- NP Brain Hospital, Istanbul, Turkey
- Faculty of Humanities and Social Sciences, Üsküdar University, Istanbul, Turkey
| | - Cihan Tastan
- Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), Üsküdar University, Istanbul, Turkey.
- Molecular Biology and Genetics Department, Faculty of Engineering and Natural Science, Üsküdar University, Istanbul, Turkey.
| |
Collapse
|
2
|
Song Y, Tian C, Lee Y, Yoon M, Yoon SE, Cho SY. Nanosensor Chemical Cytometry: Advances and Opportunities in Cellular Therapy and Precision Medicine. ACS MEASUREMENT SCIENCE AU 2023; 3:393-403. [PMID: 38145025 PMCID: PMC10740128 DOI: 10.1021/acsmeasuresciau.3c00038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 10/13/2023] [Accepted: 10/16/2023] [Indexed: 12/26/2023]
Abstract
With the definition of therapeutics now encompassing transplanted or engineered cells and their molecular products, there is a growing scientific necessity for analytics to understand this new category of drugs. This Perspective highlights the recent development of new measurement science on label-free single cell analysis, nanosensor chemical cytometry (NCC), and their potential for cellular therapeutics and precision medicine. NCC is based on microfluidics integrated with fluorescent nanosensor arrays utilizing the optical lensing effect of a single cell to real-time extract molecular properties and correlate them with physical attributes of single cells. This new class of cytometry can quantify the heterogeneity of the multivariate physicochemical attributes of the cell populations in a completely label-free and nondestructive way and, thus, suggest the vein-to-vein conditions for the safe therapeutic applications. After the introduction of the NCC technology, we suggest the technological development roadmap for the maturation of the new field: from the sensor/chip design perspective to the system/software development level based on hardware automation and deep learning data analytics. The advancement of this new single cell sensing technology is anticipated to aid rich and multivariate single cell data setting and support safe and reliable cellular therapeutics. This new measurement science can lead to data-driven personalized precision medicine.
Collapse
Affiliation(s)
- Youngho Song
- School
of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Changyu Tian
- School
of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Yullim Lee
- School
of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Minyeong Yoon
- School
of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Sang Eun Yoon
- Division
of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
| | - Soo-Yeon Cho
- School
of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| |
Collapse
|